Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)
Domains
Santé publique et épidémiologie| Origin | Files produced by the author(s) |
|---|
Journal Articles
Journal of Infection
Year : 2022
Gestionnaire HAL 3 Sorbonne Université : Connect in order to contact the contributor
https://hal.sorbonne-universite.fr/hal-03784773
Submitted on : Friday, September 23, 2022-12:49:35 PM
Last modification on : Wednesday, September 4, 2024-3:03:27 PM
Long-term archiving on : Saturday, December 24, 2022-6:44:32 PM
Dates and versions
Identifiers
- HAL Id : hal-03784773 , version 1
- DOI : 10.1016/j.jinf.2022.04.010
- PUBMED : 35398409
- PUBMEDCENTRAL : PMC8988484
Cite
Guillaume Martin-Blondel, Anne-Genevieve Marcelin, Cathia Soulié, Sofia Kaisaridi, Clovis Lusivika-Nzinga, et al.. Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). Journal of Infection, 2022, 84 (6), pp.e101-e104. ⟨10.1016/j.jinf.2022.04.010⟩. ⟨hal-03784773⟩
78
View
70
Download